- Regeneron will present 10 abstracts at ESMO 2026 (Oct 23-27, Madrid).
- Late-breaking OS update from C-POST Phase 3 trial of adjuvant Libtayo in high-risk CSCC at ~3.5 years median follow-up.
- Final analysis of Phase 2 neoadjuvant Libtayo in stage II-IV CSCC.
- Long-term OS follow-up of fianlimab plus cemiplimab in advanced melanoma from a Phase 1 study.
- Phase 2 sub-analysis and modeling of cenvacibart and amrecibart for catheter-related VTE in cancer patients.
- Phase 3 ROXI-CAT-II trial update for cenvacibart in VTE prevention in cancer patients.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card